Biomea Fusion (BMEA) Net Cash Flow (2020 - 2026)
Biomea Fusion (BMEA) posted Net Cash Flow of -$11.1 million for Q1 2026, down 221.25% sequentially from $9.2 million in Q4 2025, and up 50.39% YoY from -$7.4 million in Q1 2025.
Biomea Fusion (BMEA) Net Cash Flow (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Net Cash Flow for 7 years, with the latest figure at -$11.1 million in Q1 2026.
- Quarterly Net Cash Flow rose 50.39% year-over-year to -$11.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.8 million (up 108.1% YoY) and the FY2025 annual result came in at -$2.5 million, up 97.92% from the prior year.
- Net Cash Flow eased to -$11.1 million in Q1 2026 per BMEA's latest filing, from $9.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $136.6 million in Q2 2023 and troughed at -$31.9 million in Q1 2024.
- A 5-year average of -$5.9 million and a median of -$20.4 million in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 1866.33% in 2023, down 344.29% in 2023.
- Over 5 years, Net Cash Flow stood at -$20.4 million in 2022, then declined by 8.87% to -$22.2 million in 2023, then tumbled by 33.52% to -$29.7 million in 2024, then surged by 130.9% to $9.2 million in 2025, then sank by 221.25% to -$11.1 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$11.1 million, $9.2 million, and -$9.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | -10.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.03 Mn |
| Jun 30, 2026 | -10.03 Mn |
| Mar 31, 2026 | -11.12 Mn |
| Mar 31, 2026 | -11.12 Mn |
| Dec 31, 2025 | 9.17 Mn |
| Dec 31, 2025 | 9.17 Mn |
| Sep 30, 2025 | -9.58 Mn |
| Sep 30, 2025 | -9.58 Mn |
| Jun 30, 2025 | 20.36 Mn |
| Jun 30, 2025 | 20.36 Mn |
| Mar 31, 2025 | -22.42 Mn |
| Mar 31, 2025 | -22.42 Mn |
| Dec 31, 2024 | -29.67 Mn |
| Dec 31, 2024 | -29.67 Mn |
| Sep 30, 2024 | -25.33 Mn |
| Sep 30, 2024 | -25.33 Mn |
| Jun 30, 2024 | -31.63 Mn |
| Jun 30, 2024 | -31.63 Mn |
| Mar 31, 2024 | -31.95 Mn |
| Mar 31, 2024 | -31.95 Mn |